Archive · 24 Dec 2025
Ajanta Pharma partners with Biocon for semaglutide
Ajanta Pharma and Biocon have teamed up to sell a generic version of a diabetes and weight loss drug called semaglutide.
Ajanta will buy the drug from Biocon and sell it in 26 countries in Africa, the Middle East, and Central Asia.
They will have the sole rights to sell it in 23 of these countries and will share the rights with someone else in the other three.
This deal starts after the drug's patent expires in March 2026, and Ajanta expects to get regulatory approvals by late 2026 or early 2027.
Both companies are excited about this partnership and believe it will be a big success.
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 countries in Africa, the Middle East, and Central Asia.
Ajanta will procure the finished product from Biocon and distribute it under its own brand with exclusive rights in 23 countries and semi-exclusive rights in 3 others.
The partnership begins after the product patent expires in March 2026, with commercialization expected in late 2026 or early 2027 following regulatory approvals.
Ajanta generates over 40% of its revenue from these emerging markets and aims to build semaglutide into a high-growth brand.
Shares of Ajanta Pharma fell 1.14% on the announcement day, while Biocon's shares rose 0.4%.
- Who
- Ajanta Pharma and Biocon
- What
- Partnership to distribute generic semaglutide
- When
- Late 2026 or early 2027 (after regulatory approvals)
- Where
- 26 countries in Africa, Middle East, and Central Asia
- Why
- To target emerging markets as patents expire and capitalize on global acceptance of GLP-1 therapies
- Companies
- Ajanta Pharma, Biocon
- Drug
- Generic semaglutide (GLP-1 receptor agonist)
- Markets
- 26 countries in Africa, Middle East, and Central Asia
- Distribution
- Exclusive in 23 countries, semi-exclusive in 3
- Start Date
- Late 2026 or early 2027 (after regulatory approvals)
- Patent Expiry
- March 2026 (in most markets)
- Stock Performance
- Ajanta Pharma: -1.14% (Tuesday), -11% (YTD); Biocon: +0.4% (Tuesday), +8.7% (YTD)
Sources
Ajanta Pharma ties up with Biocon to target emerging markets for generic weight loss drug
Injectables will continue to dominate weight-loss drugs, says OneSource CEO
Ajanta Pharma signs in-licensing pact with Biocon for marketing semaglutide in 26 countries
Ajanta Pharma to sell Biocon’s semaglutide in 26 markets
